- Home
- ALXO vs XOS Comparison
ALXO vs XOS Comparison
Compare ALXO & XOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- XOS
- Stock Information
- Founded
- ALXO 2015
- XOS 2016
- Country
- ALXO United States
- XOS United States
- Employees
- ALXO N/A
- XOS N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- XOS Construction/Ag Equipment/Trucks
- Sector
- ALXO Health Care
- XOS Consumer Discretionary
- Exchange
- ALXO Nasdaq
- XOS Nasdaq
- Market Cap
- ALXO 24.0M
- XOS 30.1M
- IPO Year
- ALXO 2020
- XOS N/A
- Fundamental
- Price
- ALXO $0.56
- XOS $3.20
- Analyst Decision
- ALXO Strong Buy
- XOS Buy
- Analyst Count
- ALXO 6
- XOS 5
- Target Price
- ALXO $3.30
- XOS $8.80
- AVG Volume (30 Days)
- ALXO 456.6K
- XOS 20.8K
- Earning Date
- ALXO 05-08-2025
- XOS 05-14-2025
- Dividend Yield
- ALXO N/A
- XOS N/A
- EPS Growth
- ALXO N/A
- XOS N/A
- EPS
- ALXO N/A
- XOS N/A
- Revenue
- ALXO N/A
- XOS $48,678,000.00
- Revenue This Year
- ALXO N/A
- XOS $3.96
- Revenue Next Year
- ALXO N/A
- XOS $37.96
- P/E Ratio
- ALXO N/A
- XOS N/A
- Revenue Growth
- ALXO N/A
- XOS N/A
- 52 Week Low
- ALXO $0.41
- XOS $2.73
- 52 Week High
- ALXO $10.97
- XOS $9.15
- Technical
- Relative Strength Index (RSI)
- ALXO 59.08
- XOS 36.83
- Support Level
- ALXO $0.44
- XOS $3.23
- Resistance Level
- ALXO $0.48
- XOS $3.47
- Average True Range (ATR)
- ALXO 0.05
- XOS 0.23
- MACD
- ALXO 0.02
- XOS -0.05
- Stochastic Oscillator
- ALXO 99.16
- XOS 3.61
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About XOS Xos Inc.
Xos Inc is a fleet electrification solutions provider committed to the decarbonization of commercial transportation. Xos designs and manufactures Classes 5 through 8 battery-electric commercial vehicles that travel on last-mile, back-to-base routes of up to 200 miles per day. Xos also offers charging infrastructure products and services through Xos Energy Solutions to support electric vehicle fleets. Its products include Stepvan, MDXT, HDXT, Xosphere, and Xos Energy Solutions.